Effects of alkylating agents on dopamine D3 receptors in rat brain: Selective protection by dopamine

Brain Research

Volumn 847, Issue 1, 1999, Pages 32-37

  Zhang, Kehong ^a,b   Weiss, Nicholas T ^a,b   Tarazi, Frank I ^a,b   Kula, Nora S ^a,b   Baldessarini, Ross J ^a,b  

^a Mailman Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alkylation; Autoradiography; D3 and D2 dopamine receptor; EEDQ; NIPS

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; ALKYLATING AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EMONAPRIDE; ETICLOPRIDE; METIROSINE METHYL ESTER; N (4 ISOTHIOCYANATOPHENETHYL)SPIPERONE; PINDOLOL; RECEPTOR SUBTYPE; RESERPINE; SPIPERONE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; BRAIN REGION; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALKYLATING AGENTS; ANIMALS; BRAIN; DOPAMINE; DOPAMINE ANTAGONISTS; MALE; NEUROPROTECTIVE AGENTS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPIPERONE;

EID: 0032728611     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02024-7     Document Type: Article

References (35)

1. 2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. Mol. Pharmacol. 42:1992;856-863.
2. Baldessarini R.J., Tarazi F.I. Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev. Psychiatry. 3:1996;301-325.
3. 3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study Neuropsychopharmacology. 18:1998;305-316.
4. 2 serotonin receptor recovery. J. Neurochem. 46:1986;589-593.
5. 2 receptor mRNA. Brain Res. 564:1991;203-219.
6. 2 dopamine receptor cDNA. Nature. 336:1988;783-787.
7. 3 receptors in rat olfactory tubercle J. Pharmacol. Exp. Ther. 268:1994;935-942.
8. Crespi F., Mobius C. In vivo selective monitoring of basal levels of cerebral dopamine using voltammetry with Nafion modified (NA-CRO) carbon fibre micro-electrodes. J. Neurosci. Methods. 42:1992;149-161.
9. 3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
10. N.R. Draper, H. Smith, Applied Regression Analysis. Wiley, New York, 1966.
11. Florijn W.J., Tarazi F.I., Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 280:1997;561-569.
12. 3 receptors Eur. J. Pharmacol. 272:1995;R1-R3.
13. Gozlan H., Laporte A.M., Thibault S., Schlecter L., Bolanos F., Hamon M. Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology. 33:1994;423-431.
14. Hamblin M.W., Creese I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci. 32:1983;2247-2255.
15. 1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro. Mol. Pharmacol. 31:1987;50-57.
16. J.W. Kebabian, F.I. Tarazi, N.S. Kula, R.J. Baldessarini, Compounds selective for dopamine receptor subtypes, Drug Discovery Today (1997) 333-340.
17. Kuczenski R. Differential effects of reserpine and tetrabenazine on rat striatal synaptosomal dopamine biosynthesis and synaptosomal dopamine pools. J. Pharmacol. Exp. Ther. 201:1977;357-367.
18. 2 receptors following alkylation with EEDQ. Dev. Brain Res. 66:1992;286-289.
19. 3H ]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline Brain Res. 698:1995;146-154.
20. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49:1997;231-252.
21. 3H ]hydroxy-n,n-di-n-propyl-2-aminotetralin Proc. Natl. Acad. Sci. U.S.A. 89:1992;8155-8159.
22. Meller E., Goldstein M., Friedhoff A.J., Schweitzer J.W. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a new tool to probe CNS receptor function. Adv. Exp. Med. Biol. 235:1988;121-136.
23. 2-imidazoline sites in vitro and in vivo. J. Neurochem. 61:1993;1602-1610.
24. 2 dopamine receptors. Soc. Neurosci. Abstr. 16:1990;533. (Abstr 226.10).
25. Neve K., Molinoff P. Turnover of beta 1- and beta 2-adrenergic receptors after down-regulation or irreversible blockade. Mol. Pharmacol. 30:1986;104-111.
26. Norman A., Creese I. Effects of in vivo and vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain. Mol. Pharmacol. 30:1986;96-103.
27. Rebec G.V. Real-time assessments of dopamine function during behavior: single-unit recording, iontophoresis, and fast-scan cyclic voltammetry in awake, unrestrained rats. Alcohol. Clin. Exp. Res. 22:1998;32-40.
28. Sibley D.R., Monsma F.J., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35:1993;391-415.
29. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
30. 4-like receptors. Neuroscience. 83:1998;169-176.
31. Tarazi F.I., Florijn W.J., Creese I. Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience. 78:1997;985-996.
32. 4-like dopamine receptors. Neuropsychopharmacology. 17:1997;186-196.
33. 2 dopamine receptors in brain. J. Pharmacol. Exp. Ther. 257:1991;608-615.
34. 3 sites. Brain Res. 792:1998;324-326.
35. 4 receptors in rat brain by N-(p-isothiocyanatophenethyl)spiperone, Neurosci. Lett. (in press).